CN105277638A - Monoclonal antibody IgG mass spectrometry sequencing method - Google Patents
Monoclonal antibody IgG mass spectrometry sequencing method Download PDFInfo
- Publication number
- CN105277638A CN105277638A CN201410350750.1A CN201410350750A CN105277638A CN 105277638 A CN105277638 A CN 105277638A CN 201410350750 A CN201410350750 A CN 201410350750A CN 105277638 A CN105277638 A CN 105277638A
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- antibody igg
- heavy chain
- light chain
- cdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to a monoclonal antibody IgG mass spectrometry sequencing method including the following steps: carrying out reductive alkylation of a monoclonal antibody IgG; separating a heavy chain and a light chain of the reductive-alkylated monoclonal antibody IgG by an electrophoresis method; carrying out in-gel digestion of the heavy chain and the light chain of the monoclonal antibody IgG to obtain polypeptide fragments; adding the polypeptide fragments obtained from digestion into an LC-MS/MS mass spectrometer to obtain a fingerprint atlas; analyzing and finding out CDR1/2/3 sequences through the fingerprint atlas; and sequencing the CDR1/2/3 sequences.
Description
Technical field
The present invention relates to biological technical field, be specifically related to a kind of monoclonal antibody IgG mass spectrum sequence measurement.
Background technology
At present, mostly the preparation of monoclonal antibody IgG is to be prepared by hybridoma, so just need the hybridoma cell strain obtaining producing high specific and sensitivity by high-throughout screening, and produce high-quality monoclonal antibody IgG with this hybridoma cell strain.The high flux screening workload of hybridoma is huge, will ensure the stability of the hybridoma screened simultaneously, needs strict condition of storage.Therefore engineered means can be used, obtain the monoclonal antibody of high specific and sensitivity, this just needs the protein sequence being obtained high-quality monoclonal antibody IgG by order-checking, thus derives its gene order, whereby, the monoclonal antibody IgG of high-quality is prepared by the mode of genetic recombination.In view of mass-spectrometric technique is more and more extensive in the application in albumen field, the demand of monoclonal antibody technology of preparing development trend simultaneously, need a kind of new method efficiently measuring monoclonal antibody IgG sequence accurately, thus need to develop a kind of suitable monoclonal antibody sequencing technologies, for the preparation of high-quality monoclonal antibody IgG.
Summary of the invention
In order to solve above technical matters, the invention provides a kind of monoclonal antibody IgG mass spectrum sequence measurement, when the order-checking of monoclonal antibody IgG is reduced to CDR1/2/3 sequencing, monoclonal antibody IgG order-checking difficulty declines rapidly.
The present invention is achieved through the following technical solutions:
A kind of monoclonal antibody IgG mass spectrum sequence measurement, comprises the following steps:
(1) by monoclonal antibody IgG reductive alkylation;
(2) by electrophoresis method, the described monoclonal antibody IgG of reductive alkylation is separated heavy chain and light chain;
(3) heavy chain of in-gel digestion monoclonal antibody IgG and light chain obtain polypeptide fragment;
(4) enzyme is cut the polypeptide fragment obtained and is loaded onto LC-MS/MS instrument;
(5) CDR1/2/3 sequence is found out by NanoLC fingerprint map analyzing;
(6) CDR1/2/3 sequence.
In technique scheme, the reductive alkylation in described step (1) adopts DTT-IAM pattern.
In technique scheme, the electrophoresis method in described step (2) is conventional SDS-PAGE electrophoresis.
In technique scheme, the heavy chain of the in-gel digestion monoclonal antibody IgG in described step (3) and light chain adopt conventional in-geldigestion method.
In technique scheme, adding mass spectrometric enzyme in described step (4), to cut polypeptide sample size be 5-15 μ L.
The present invention is combined by LC-MS/MS method and receives upgrade liquid chromatogram method (NanoLC) order-checking of monoclonal antibody IgG is reduced to CDR1/2/3 sequencing, polypeptide spectrogram potential for CDR1/2/3 can be locked onto some region by the analysis of NanoLC finger-print, then these spectrograms of labor and obtain final CDR1/2/3 peptide sequence information, then the conserved sequence in monoclonal antibody IgG and final CDR1/2/3 peptide sequence are carried out splicing and can obtain complete monoclonal antibody IgG amino acid sequence, monoclonal antibody IgG order-checking difficulty is declined rapidly.
Embodiment
Below in conjunction with embodiment, technical scheme of the present invention is described in detail.
Embodiment one
NGAL antibody mass spectrum checks order:
The order-checking of NGAL antibody mass spectrum comprises the following steps: 1, homemade NGAL monoclonal antibody (heavy chain amino acid sequence of antibody is shown in sequence table 1, and the light-chain amino acid sequence of antibody is shown in sequence table 2) is carried out reductive alkylation; 2, SDS-PAGE electrophoresis is through the NGAL monoclonal antibody IgG of reductive alkylation, is separated heavy chain and light chain; 3, the heavy chain of in-gel digestion NGAL monoclonal antibody IgG and light chain obtain polypeptide fragment respectively; 4, enzyme cuts LC-MS/MS instrument on the polypeptide that obtains; 5, nanoLC fingerprint figure analysis; 6, spectrogram qualification and CDR1/2/3 qualification.The operation of concrete each step is as follows:
1, NGAL monoclonal antibody reductive alkylation
Monoclonal antibody IgG reductive alkylation adopts DTT-IAM pattern, and DDT (Dithiothreitol, dithiothreitol (DTT)) is for Reduction of Disulfide, and IAM (iodacetyl ammonia) is for closed sulfydryl.The operation steps that the method is concrete is as follows: the IgG antibody solution (i.e. 20 μ g) 1. getting 20 μ L operates for reductive alkylation; 2. 0.2 μ LDTT is added, 56 DEG C of water-bath 45min; 3. ice bath 5min; Thoroughly cool to room temperature; 4. under dark condition, 2 μ LIAM are added, reaction 60min; 5. 13000rpm, centrifugal 5min, removes precipitation; 6. take out supernatant, supernatant is used for follow-up SDS-PAGE electrophoresis.
2, the heavy chain of SDS-PAGE electrophoretic separation antibody and light chain
SDS-PAGE electrophoresis is through the monoclonal antibody IgG of reductive alkylation, and be separated in heavy chain and light chain, SDS-PAGE electrophoresis adopts conventional SDS-PAGE electrophoresis method.
3, the heavy chain of in-gel digestion NGAL monoclonal antibody IgG and light chain
The heavy chain obtained electrophoretic separation by pancreatin, pepsin and elastoser respectively after electrophoretic separation completes and light chain carry out in-gel digestion, and its concrete enzyme cuts through journey and parameter is as follows:
Pancreatin in-gel digestion: adopt pancreatin to the heavy chain of monoclonal antibody IgG and light chain carry out in-gel digestion obtain polypeptide fragment time, in-gel digestion monoclonal antibody IgG adopts conventional in-geldigestion method.The operation steps that the method is concrete is as follows: 1. clean and decolour: protein spots bale cutting instrument is cut glue, is placed in 96 orifice plates.200/A1 destainer (100mmol/L sodium thiosulfate and 30mmol/L potassium ferricyanide solution mix according to 1:1) is added in containing each hole of micelle, after leaving standstill 30min, abandoning supernatant.Then add 200/ μ L water cleaning, after leaving standstill 30min, abandon supernatant.Repeat this step until micelle becomes colorless; 2. dehydrate: add after 200 μ L acetonitriles leave standstill 30min in micelle, abandon supernatant.Repeat this step to dewater completely to gel and bleach.After acetonitrile sucking-off being given up, micelle is placed in 37 DEG C to bone dry; 3. enzyme vacuole is swollen: after the trypsase 20mmol/L ammonium bicarbonate soln of order-checking level is formulated as concentration 12.5ng/mL, add appropriate enzyme liquid in micelle, and places 30min in 4 DEG C and micelle is steeped completely rise.Then the enzyme liquid that sucking-off is unnecessary discards, to prevent the peptide section occurring too much trypsase auto-degradation during Mass Spectrometer Method; 4. enzymolysis: the 25mmol/L ammonium bicarbonate soln adding about 5 μ L covers micelle, to prevent solution dry in enzymolysis process.Be placed in 37 DEG C of temperature-controlled box inside holding 12 ~ 16h; 5. extract: 0.1%TFA and 50% acetonitrile of the 60 μ L of the micelle after enzymolysis extract 3 times, each 20min, merge extract; 6. concentrate: drain under Vacuum Concentration instrument condition.
Adopt pepsin and elastoser to the heavy chain of monoclonal antibody IgG and light chain carry out in-gel digestion obtain polypeptide fragment time, itself and when adopting pancreatin to carry out in-gel digestion difference be: the damping fluid adopted when 4. enzymolysis is different, and that pepsin adopts when 4. enzymolysis is 5%TFA; When adopting elastoser to carry out 4. enzymolysis, damping fluid used is the Trisbuffer of pH=9.When pancreatin, pepsin and elastoser in-gel digestion except damping fluid during 4. enzymolysis is different, remaining parameter and operation steps are all the same.
4, enzyme cuts LC-MS/MS instrument on the polypeptide that obtains
Adopt after various enzyme completes in-gel digestion process, enzyme is cut the polypeptide fragment obtained and go up LC-MS/MS instrument respectively, described mass spectrometer is the mass spectrometer of various model, the TripleTOF5600-plus mass spectrometer of preferred ABSCIEX company, entering mass spectrometric enzyme, to cut polypeptide sample size be 5-15 μ L, is preferably 10 μ L.
5, NanoLC fingerprint figure analysis
NanoLC fingerprint figure analysis is that polypeptide sample enters mass spectrometer and needs after obtaining mass spectrometric data to analyze the heavy chain of IgG and the fingerprint image of light chain, the retention time of conserved sequence in IgG, electric charge, peak intensity and applied sample amount are carried out one_to_one corresponding, then determines the fingerprint image of monoclonal antibody IgG.The analysis of fingerprint image can lock the hypotype of IgG1/2/3.IgG has four kinds of hypotypes at least, the IgG1/2/3/4 of the such as mankind, the IgG1/2a/2b/3 etc. of mouse.The difference of different subtype is-COOH terminal sequence.Therefore, the singularity of monoclonal antibody order-checking is that IgG only only has the sequence in CDR1/2/3 region to be variable, and the sequence in other region is all conservative.Therefore, to compare common protein sequencing difficulty much lower for IgG protein sequencing.IgG comprises heavy chain (VDJ restructuring) and light chain (VJ restructuring) two long-chain polypeptide, and two polypeptide are connected together by disulfide bond and produce complete IgG antibody.After IgG enzymolysis, produce a lot of polypeptide, because conserved region is the same, therefore, it is consistent (at least closely similar) that the conserved region enzyme of same species cuts result.Different peptide sequences is from the polypeptide in CDR1/2/3 region, and these polypeptide show skew on the collection of illustrative plates of NanoLC, and the polypeptide of these skews is exactly CDR1/2/3 polypeptide.This is the key message of polypeptide NanoLC fingerprint image, the retention time of potential CDR1/2/3 sequence, peak intensity and m/z information (retention time data are in table one and table two) can be got by NanoLC fingerprint image, then can select these polypeptide specially and carry out MS/MS qualification.
Table one NGAL monoclonal antibody IgG heavy chain each enzymolysis spectrogram retention time
Table two NGAL monoclonal antibody IgG light chain each enzymolysis spectrogram retention time
6, spectrogram qualification and CDR1/2/3 qualification
When spectrogram qualification and CDR1/2/3 qualification, when the order-checking of monoclonal antibody IgG is reduced to CDR1/2/3 sequencing, monoclonal antibody IgG order-checking difficulty declines rapidly.Polypeptide spectrogram potential for CDR1/2/3 can be locked onto some region by the analysis of NanoLC fingerprint image, then these spectrograms of labor and obtain final CDR1/2/3 peptide sequence information.Then the conserved sequence in monoclonal antibody IgG and final CDR1/2/3 peptide sequence are carried out splicing and can obtain complete monoclonal antibody IgG amino acid sequence.Various enzyme cuts the heavy chain of NGAL monoclonal antibody and light chain spectrogram qualification result and polypeptide splicing result as shown in following table three and table four:
Table three NGAL monoclonal antibody IgG heavy chain each enzymolysis spectrogram qualification result
Table four NGAL monoclonal antibody IgG light chain each enzymolysis spectrogram qualification result
Use proteincoveragesummarizer software carries out polypeptide (peptide) and IgG antibody sequence carries out coverage rate analysis.Found that sequence of heavy chain almost successful matching completely (except Fc end has an amino acid to fail to match, but Fc is known array, has no effect to order-checking), namely variable region is surveyed logical completely; And sequence of light chain coverage rate is 97.66%, what fail that the match is successful is also the sequence of conserved region, and this sequence is also known array, and variable region is also complete tested logical.
It should be noted last that, above embodiment is only in order to illustrate implementer's case of this material and unrestricted, although with reference to preferred embodiment to invention has been detailed description, those of ordinary skill in the art is to be understood that, can modify to technical scheme of the present invention or equivalent replacement, and not departing from the spirit and scope of technical solution of the present invention, it all should be encompassed in the middle of right of the present invention.
SEQUENCELISTING
<110> Shen He clouds
<120> monoclonal antibody IgG mass spectrum sequence measurement
<130>
<160>2
<170>PatentInversion3.5
<210>1
<211>445
<212>PRT
<213> artificial sequence
<400>1
ArgCysAsnCysArgSerLeuAspLeuAlaTrpTrpArgProHisArg
151015
AlaCysProSerHisAlaProSerGlnValSerGlnLeuThrAsnTyr
202530
GlyValHisTrpValArgGlnProProGlyLysGlyLeuGluTrpLeu
354045
ValValIleTrpGlyAspGlySerThrThrSerAsnSerAlaLeuLys
505560
SerArgLeuSerIleSerLysAspAsnSerLysSerGlnValPheLeu
65707580
LysMetAsnSerLeuGlnThrAspAspThrAlaMetTyrTyrCysAla
859095
ArgHisGlyGluAlaTyrLeuPheValMetAspTyrTrpGlyGlnGly
100105110
ThrThrValThrValSerSerAlaSerThrLysGlyProSerValPhe
115120125
ProLeuAlaProCysSerArgSerThrSerGluSerThrAlaAlaLeu
130135140
GlyCysLeuValLysAspTyrPheProGluProValThrValSerTrp
145150155160
AsnSerGlyAlaLeuThrSerGlyValHisThrPheProAlaValLeu
165170175
GlnSerSerGlyLeuTyrSerLeuSerSerValValThrValProSer
180185190
SerAsnPheGlyThrGlnThrTyrThrCysAsnValAspHisLysPro
195200205
SerAsnThrLysValAspLysThrValGluArgLysCysCysValGlu
210215220
CysProProCysProAlaProProValAlaGlyProSerValPheLeu
225230235240
PheProProLysProLysAspThrLeuMetIleSerArgThrProGlu
245250255
ValThrCysValValValAspValSerHisGluAspProGluValGln
260265270
PheAsnTrpTyrValAspGlyValGluValHisAsnAlaLysThrLys
275280285
ProArgGluGluGlnPheAsnSerThrPheArgValValSerValLeu
290295300
ThrValValHisGlnAspTrpLeuAsnGlyLysGluTyrLysCysLys
305310315320
ValSerAsnLysGlyLeuProAlaProIleGluLysThrIleSerLys
325330335
ThrLysGlyGlnProArgGluProGlnValTyrThrLeuProProSer
340345350
ArgGluGluMetThrLysAsnGlnValSerLeuThrCysLeuValLys
355360365
GlyPheProTyrSerAspIleAlaValGluTrpGluSerAsnGlyGln
370375380
ProGluAsnAsnTyrLysThrThrProProMetLeuAspSerAspGly
385390395400
SerPhePheLeuTyrSerLysLeuThrValAspLysSerArgTrpGln
405410415
GlnGlyAsnValPheSerCysSerValMetHisGluAlaLeuHisAsn
420425430
HisTyrThrGlnLysSerLeuSerLeuSerProGlyLys
435440445
<210>2
<211>214
<212>PRT
<213> artificial sequence
<400>2
AspIleGluLeuThrGlnSerProAlaThrLeuSerValThrProGly
151015
AspSerValSerLeuSerCysArgAlaSerGlnSerIleSerAsnAsn
202530
LeuHisTrpTyrGlnGlnLysSerHisGluSerProArgLeuLeuIle
354045
LysSerAlaSerGlnSerIleSerGlyIleProSerArgPheSerGly
505560
SerGlySerGlyThrAspPheSerLeuSerIleAsnSerValGluThr
65707580
GluAspPheGlyMetPhePheCysGlnGlnSerAsnSerTrpArgLeu
859095
ThrPheGlyAlaGlyThrLysLeuGluLeuLysArgThrValAlaAla
100105110
ProSerValPheIlePheProProSerAspGluGlnLeuLysSerGly
115120125
ThrAlaSerValValCysLeuLeuAsnAsnPheTyrProArgGluAla
130135140
LysValGlnTrpLysValAspAsnAlaLeuGlnSerGlyAsnSerGln
145150155160
GluSerValThrGluGlnAspSerLysAspSerThrTyrSerLeuSer
165170175
SerThrLeuThrLeuSerLysAlaAspTyrGluLysHisLysValTyr
180185190
AlaCysGluValThrHisGlnGlyLeuSerSerProValThrLysSer
195200205
PheAsnArgGlyGluCys
210
Claims (5)
1. a monoclonal antibody IgG mass spectrum sequence measurement, is characterized in that, comprises the following steps:
(1) by monoclonal antibody IgG reductive alkylation;
(2) by electrophoresis method, the described monoclonal antibody IgG of reductive alkylation is separated heavy chain and light chain;
(3) heavy chain of in-gel digestion monoclonal antibody IgG and light chain obtain polypeptide fragment;
(4) enzyme is cut the polypeptide fragment obtained and is loaded onto LC-MS/MS instrument;
(5) CDR1/2/3 sequence is found out by NanoLC fingerprint map analyzing;
(6) CDR1/2/3 sequence.
2. monoclonal antibody IgG mass spectrum sequence measurement as claimed in claim 1, is characterized in that, the reductive alkylation in described step (1) adopts DTT-IAM pattern.
3. monoclonal antibody IgG mass spectrum sequence measurement as claimed in claim 1, it is characterized in that, the electrophoresis method in described step (2) is conventional SDS-PAGE electrophoresis.
4. monoclonal antibody IgG mass spectrum sequence measurement as claimed in claim 1, it is characterized in that, the heavy chain of the in-gel digestion monoclonal antibody IgG in described step (3) and light chain adopt conventional in-geldigestion method.
5. monoclonal antibody IgG mass spectrum sequence measurement as claimed in claim 1, is characterized in that, adding mass spectrometric enzyme in described step (4), to cut polypeptide sample size be 5-15 μ L.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410350750.1A CN105277638A (en) | 2014-07-22 | 2014-07-22 | Monoclonal antibody IgG mass spectrometry sequencing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410350750.1A CN105277638A (en) | 2014-07-22 | 2014-07-22 | Monoclonal antibody IgG mass spectrometry sequencing method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105277638A true CN105277638A (en) | 2016-01-27 |
Family
ID=55147008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410350750.1A Pending CN105277638A (en) | 2014-07-22 | 2014-07-22 | Monoclonal antibody IgG mass spectrometry sequencing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105277638A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106645456A (en) * | 2016-10-13 | 2017-05-10 | 上海市食品药品检验所 | Mass-spectrum-technology-based sequencing method for monoclonal antibody medicine amino acid sequence |
| CN107525934A (en) * | 2016-06-21 | 2017-12-29 | 张效龙 | A kind of method for determining antibodies in blood amino acid sequence |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1344370A (en) * | 1999-03-23 | 2002-04-10 | 拜奥维森有限公司 | Protein isolation and analysis |
| EP2123678A1 (en) * | 2003-11-10 | 2009-11-25 | Schering Corporation | Identifying acceptor germline sequences for humanized antibodies |
| CN103145834A (en) * | 2013-01-17 | 2013-06-12 | 广州泰诺迪生物科技有限公司 | Antibody humanization transformation method |
| CN103842379A (en) * | 2011-03-09 | 2014-06-04 | 细胞信号科技公司 | Methods and reagents for creating monoclonal antibodies |
-
2014
- 2014-07-22 CN CN201410350750.1A patent/CN105277638A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1344370A (en) * | 1999-03-23 | 2002-04-10 | 拜奥维森有限公司 | Protein isolation and analysis |
| EP2123678A1 (en) * | 2003-11-10 | 2009-11-25 | Schering Corporation | Identifying acceptor germline sequences for humanized antibodies |
| CN103842379A (en) * | 2011-03-09 | 2014-06-04 | 细胞信号科技公司 | Methods and reagents for creating monoclonal antibodies |
| CN103145834A (en) * | 2013-01-17 | 2013-06-12 | 广州泰诺迪生物科技有限公司 | Antibody humanization transformation method |
Non-Patent Citations (4)
| Title |
|---|
| BERNHARD GRANVOGL 等: "Sample preparation by in-gel digestion for mass spectrometry-based proteomics", 《ANAL BIOANAL CHEM》 * |
| DOMINIQUE DE COSTA 等: "Sequencing and Quantifying IgG Fragments and Antigen-Binding Regions by Mass Spectrometry", 《JOURNAL OF PROTEOME RESEARCH》 * |
| LENNARD J. M. DEKKER 等: "An antibody-based biomarker discovery method by mass spectrometry sequencing of complementarity determining regions", 《ANALYTICAL AND BIOANALYTICAL CHEMISTRY》 * |
| WAN CHEUNG CHEUNG 等: "A proteomics approach for the identification and cloning of monoclonal antibodies from serum", 《NATURE BIOTECHNOLOGY》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107525934A (en) * | 2016-06-21 | 2017-12-29 | 张效龙 | A kind of method for determining antibodies in blood amino acid sequence |
| CN106645456A (en) * | 2016-10-13 | 2017-05-10 | 上海市食品药品检验所 | Mass-spectrum-technology-based sequencing method for monoclonal antibody medicine amino acid sequence |
| CN106645456B (en) * | 2016-10-13 | 2019-11-08 | 上海市食品药品检验所 | The sequencing approach of monoclonal antibody drug amino acid sequence is realized based on mass-spectrometric technique |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Piersma et al. | Whole gel processing procedure for GeLC-MS/MS based proteomics | |
| Schoemaker et al. | Photo-induced joining of a transfer RNA with its cognate aminoacyl-transfer RNA synthetase | |
| DE60317314D1 (en) | METHOD AND DEVICE FOR IDENTIFICATION AND ASSIGNMENT OF BIOMOLECULES | |
| CN105518447A (en) | Method for preparing peptide fragments, kit for preparing peptide fragments to be used therein, and analysis method | |
| CN108072555A (en) | A kind of analysis and processing method of protein methylation and its application | |
| CN109425662A (en) | A kind of method and system for identifying albumen | |
| CN109863395B (en) | Molecular weight method for identifying and monitoring cracked immunoglobulin | |
| CN104237363A (en) | Protein quantification method | |
| CN105277638A (en) | Monoclonal antibody IgG mass spectrometry sequencing method | |
| CN113484449B (en) | High-throughput quantitative and qualitative protein analysis method | |
| Wang et al. | Spatial differences in an integral membrane proteome detected in laser capture microdissected samples | |
| CN106324069B (en) | A kind of mass spectrum acquisition mode based on quick scanning and without dynamic exclusion | |
| CN110426522A (en) | A kind of identification method of Vipera russelli venom and its application | |
| CN113777178A (en) | Proteomics background library based on mixed spectrogram library, and construction method and application thereof | |
| CN103033628A (en) | Preparation method and application of individual whole proteome chip | |
| CN103512997A (en) | Two-dimensional short-gradient high-efficiency protein component separation and identification method | |
| CN107014935A (en) | A kind of IgG sugar-type detection batch pre-treating method of blood plasma or serum | |
| CN105866262B (en) | A kind of method of quick identification chondroitin sulfate A (CSA) and C | |
| CN105866429B (en) | Biomolecular labeling and quantitative analysis method based on charged isotope reagent | |
| CN109355286A (en) | A method of exempting from pre-treatment automation and extracts large volume whole blood DNA | |
| CN109596729A (en) | Application of the construction method and soybean protein express spectra of soybean seed protein express spectra in analysis Biometabolic pathway | |
| CN115181733B (en) | Peptide fragment composition for relatively quantitatively analyzing porcine ferritin heavy chain FTH1 and application thereof | |
| CN115043905B (en) | Peptide fragment composition for relatively quantitatively analyzing pig glycine guanyltransferase GATM and application thereof | |
| Carreira et al. | Indirect ultrasonication for protein quantification and peptide mass mapping through mass spectrometry-based techniques | |
| KR20130030464A (en) | Apparatus for on-line micro-hollow fiber enzymatic reactor and method for on-line proteomics using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20180110 Address after: 430000 Hubei Wuhan city East Lake Development Zone Hi-tech Avenue 818 Gao medical equipment garden B11 No. 2 Applicant after: WUHAN GENECREATE BIO-ENGINEERING CO., LTD. Address before: 430223 Hubei Wuhan city East Lake Development Zone Hi-tech Avenue 818 Gao medical equipment garden B11 Applicant before: Shen Hexiao |
|
| TA01 | Transfer of patent application right | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160127 |
|
| RJ01 | Rejection of invention patent application after publication |